Online Exclusives

Online Exclusives

CAR T-Cell Therapy Induces Complete Remissions in Aggressive Non-Hodgkin Lymphoma

In the phase II ZUMA-1 trial of patients with aggressive non-Hodgkin lymphoma, treatment with the experimental chimeric antigen receptor T-cell (CAR T-cell) therapy, KTE-C19,...

ABIM Survey Shows Majority of Physicians’ Want Shorter, More Frequent MOC Exams

The American Board of Internal Medicine (ABIM) surveyed board-certified physicians about potential changes to the Maintenance of Certification (MOC) program requirements, and the results...

FDA Approves Implant for the Treatment of Opioid Dependence

The U.S. Food and Drug Administration approved the first buprenorphine implant for the maintenance treatment of opioid dependence. The implant, which consists of four,...

FDA Accepts Application to Review New Sickle Cell Disease Treatment

The U.S. Food and Drug Administration (FDA) accepted a New Drug Application (NDA) from Emmaus Life Sciences for its orally administered pharmaceutical grade L-glutamine...

Study Finds Hematopoietic Cell Transplants May Age Immune Cells

A study funded by the National Institutes of Health found that certain blood cancer treatments may lead to the premature aging of immune cells. Researchers...

Study Finds Patients Are Less Physically Active One Year After Cancer Diagnosis

Research has shown that physical activity can help reduce cancer risk, and can help maintain quality of life and accelerate recovery after a cancer...

Conference Coverage: ELOQUENT-2: Adding Elotuzumab to Standard Therapy Reduces Progression Risk for Multiple Myeloma...

CHICAGO—According to interim results of the phase III, randomized, open-label ELOQUENT-2 study, elotuzumab may offer a new treatment option for patients with relapsed multiple...

EMA Recommends Conditional Approval for Daratumumab

The European Medicines Agency (EMA) has recommended the approval of daratumumab for adult patients with multiple myeloma who have already failed standard treatment. This...

JCAR015 Trial Temporarily Put on Clinical Hold by FDA, Then Allowed to Resume

After the U.S. Food and Drug Administration (FDA) placed a phase II chimeric antigen receptor (CAR) trial on clinical hold due to patient deaths,...

NHLBI to Provide Funding Opportunities to Advance Hematopoietic Cell Transplantation

The National Heart, Lung, and Blood Institute (NHLBI) released a notice stating its intention to publish funding opportunities and solicit applications for the Data...
Advertisement

Current Issue

April 2019, Volume 5, Issue 5

This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.